

EMA/281206/2011

European Medicines Agency decision

P/107/2011

of 6 May 2011

on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation Factor VIII / von Willebrand Factor, (EMEA-000312-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/107/2011

of 6 May 2011

on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation Factor VIII / von Willebrand Factor, (EMA-000312-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/164/2009 issued on 14 August 2009 and the decision P/140/2010 issued on 30 July 2010,

Having regard to the application submitted by CSL Behring on 1 February 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 March 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for human coagulation Factor VIII / von Willebrand Factor, powder and solvent for solution for injection, powder and solvent for solution for infusion, intravenous use are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to CSL Behring, Emil-von-Behring-Str.76, 35041 Marburg, Germany.

Done at London, 6 May 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)

EMA/PDCO/157267/2011

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000312-PIP01-08-M02

Scope of the application

Active substance(s):

Human coagulation Factor VIII

Von Willebrand Factor

Condition(s):

Treatment of hereditary Factor VIII deficiency

Treatment of von Willebrand disease

Pharmaceutical form(s):

Powder and solvent for solution for injection

Powder and solvent for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

CSL Behring

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, CSL Behring submitted to the European Medicines Agency on 1 February 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/164/2009 issued on 14 August 2009 and P/140/2010 issued on 30 July 2010.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 23 February 2011.

Scope of the modification

Some measures and timelines of the original opinion have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan.

The Norwegian and Icelandic Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 18 March 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver

1. Waiver

1.1. Condition

Treatment of hereditary Factor VIII deficiency (Haemophilia A) (previously untreated patients)

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age,
- for powder and solvent for solution for injection for intravenous use,
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

Treatment of hereditary Factor VIII deficiency (Haemophilia A) (Subjects with haemophilia A who have developed high-titer inhibitors to factor VIII (FVIII))

- Infants from birth to less than 28 days,
- Adolescents from 12 to less than 18 years,
- for powder and solvent for solution for injection for intravenous use,
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition to be investigated

Treatment of hereditary Factor VIII deficiency

2.1.1. Indication targeted by the PIP

- Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital Factor VIII deficiency),
- Immune tolerance induction in patients who have inhibitors to factor VIII.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Previously treated children from birth to less than 18 years of age

Children from 1 month to less than 12 years of age for subjects who have developed high-titer inhibitors to Factor VIII

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection, intravenous use

Powder and solvent for solution for infusion, intravenous use

2.1.4. Studies

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical		Not applicable.
Clinical	3	<i>Study 1:</i> Double blind, randomised, multicentre, cross-over trial to evaluate pharmacokinetics, safety, efficacy, of Human Factor VIII/von Willebrand Factor in previously treated children from 12 to less than 18 years of age (and adults) with haemophilia A. <i>Study 2:</i> Open-label, multicentre, trial to evaluate pharmacokinetics, safety and efficacy, of Human Factor VIII/von Willebrand Factor in previously treated children from birth to less than 12 years of age with haemophilia A. <i>Study 3:</i> Open-label, multicentre, trial to evaluate safety and efficacy of Human Factor VIII/von Willebrand Factor in children from 1 month to less than 12 years of age with haemophilia A who have developed high responding antibodies to FVIII.

2.2. Condition to be investigated

Treatment of von Willebrand disease

2.2.1. Indication targeted by the PIP

Prophylaxis and treatment of haemorrhage or surgical bleeding in von Willebrand disease, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Powder and solvent for solution for injection, intravenous use

Powder and solvent for solution for infusion, intravenous use

2.2.4. Studies

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical		Not applicable.
Clinical	2	<i>Study 4:</i> open-label, multicentre trial to evaluate pharmacokinetics, safety, efficacy, of Human Factor VIII/von Willebrand Factor in children from 12 to less than 18 years of age (and adults) with Von Willebrand Disease. <i>Study 5:</i> open-label, multicentre trial to evaluate pharmacokinetics, safety, efficacy, of Human Factor VIII/von Willebrand Factor in children from birth to less than 12 years of age with Von Willebrand Disease.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2015
Deferral for one or more studies contained in the paediatric investigation plan:	Yes